MyHeartCode uses DNA methylation analysis across millions of genomic sites to assess cardiovascular aging and metabolic function over a three- to four-month window, offering a dynamic biological picture beyond single-point cholesterol measurement. This approach addresses a critical gap for individuals with family history of heart disease or prior cardiovascular events—populations for whom conventional lipid panels provide insufficient insight into underlying disease trajectory.
Key Points
- Measures 3 million CpG methylation sites instead of single cholesterol snapshot
- Tracks cardiovascular aging patterns over 3-4 months of biological history
- Assesses ten domains including metabolic health, inflammation, immune function, stress biomarkers
Longevity Analysis
Epigenetic methylation patterns reflect cumulative physiological stress and adaptation across multiple body systems—a window into how tissues are actually aging rather than static risk factors. For individuals with genetic predisposition or prior events, this signal-level resolution enables early detection of accelerating cardiovascular aging before clinical events occur, shifting the intervention point upstream. The multi-system readout (metabolic, inflammatory, immune, mitochondrial function, toxin exposure) recognizes that cardiovascular health cannot be isolated from systemic aging patterns, allowing for more targeted optimization strategies.
Original published by Longevity.Technology, by Kyle Umipig.